- Home
- CDLR vs ATAI Comparison
CDLR vs ATAI Comparison
Compare CDLR & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CDLR | ATAI |
|---|---|---|
| Founded | 2008 | 2018 |
| Country | Denmark | United States |
| Employees | N/A | 54 |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.3B |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | CDLR | ATAI |
|---|---|---|
| Price | $24.73 | $3.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $15.57 |
| AVG Volume (30 Days) | 76.3K | ★ 4.6M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $308,000.00 |
| Revenue This Year | $142.95 | N/A |
| Revenue Next Year | $70.44 | $285.00 |
| P/E Ratio | $7.39 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $15.37 | $1.15 |
| 52 Week High | $26.79 | $6.73 |
Technical Indicators
Market Signals| Indicator | CDLR | ATAI |
|---|---|---|
| Relative Strength Index (RSI) | 50.87 | 46.97 |
| Support Level | $23.38 | $3.41 |
| Resistance Level | $25.21 | $4.40 |
| Average True Range (ATR) | 0.64 | 0.26 |
| MACD | -0.28 | 0.01 |
| Stochastic Oscillator | 35.66 | 31.70 |
Price Performance
Historical ComparisonAbout CDLR Cadeler AS
Cadeler AS is an offshore wind farm vessel contractor. It is engaged in offshore wind farm construction, maintenance, and decommissioning and provides marine and engineering operations to the wind industry, focusing on safety and the environment. The company operates six offshore jack-up wind farm installation vessels. In addition to wind farm installation, these vessels can perform maintenance, construction, decommissioning, and other tasks within the offshore industry.
About ATAI ATAI Life Sciences N.V.
AtaiBeckley Inc is a clinical-stage biopharmaceutical company on a mission to transform patient outcomes by developing effective, rapid-acting, and convenient mental health treatments. AtaiBeckley's pipeline of novel therapies includes BPL-003 (mebufotenin benzoate nasal spray) for treatment-resistant depression (TRD), VLS-01 (DMT buccal film) for TRD and EMP-01 ((R)-MDMA HCI) for social anxiety disorder, which are in Phase 2 clinical development.